A digest of what's worth reading across Psychedelic Alpha, Double Blind, and Lucid News this week.
## Senate Bill Would Create VA Office of Novel Therapeutics
Sen. Tim Sheehy (R-MT) introduced the Veterans Health Administration Novel Therapeutics Preparedness Act. It would create a dedicated office within the VA to coordinate research and eventual implementation of psychedelic-assisted therapies — essentially building the institutional infrastructure before FDA approval arrives.
[Source: Lucid News](https://www.lucid.news/new-federal-bill-aims-to-establish-va-office-of-novel-therapeutics/)
## Microdosing Works on the Day You Do It. That Might Be It.
The largest naturalistic study of microdosers ever conducted — 1,435 participants keeping daily diaries — found improvements in creativity, focus, wellbeing, and productivity on dosing days. On all other days, no statistically significant effect. Lead author Dr. Michelle St. Pierre draws an analogy to a vitamin supplement or cup of coffee rather than a treatment for mental illness.
[Source: Lucid News](https://www.lucid.news/authors-of-largest-microdosing-study-suggest-benefits-limited-to-dosing-day/)
## FDA Lifts Clinical Hold on 5-MeO-DMT Candidate GH001
GH Research's inhalable 5-MeO-DMT drug GH001 had been on FDA clinical hold for two years. The hold was lifted in early January 2026. Phase 2 data showed a 15.5-point reduction on the MADRS depression scale versus placebo at day 8, with 57.5% of patients in remission.
[Source: Lucid News](https://www.lucid.news/federal-support-for-u-s-psychedelic-research-accelerates-5-meo-dmt-clinical-trials/)
## Ibogaine's Mechanism Is Weirder Than Anyone Thought
Columbia chemist Dalibor Sames proposes a new pharmacological framework called "matrix pharmacology" — ibogaine appears to affect multiple neurotransmitter systems simultaneously in ways that don't fit existing drug categories. Noribogaine inhibits serotonin reuptake and VMAT2 at the same time, which no other known drug does.
[Source: Lucid News](https://www.lucid.news/new-theories-and-findings-from-the-frontier-of-ibogaine-research/)
## Inside Lykos: Billionaire Takeover and Doblin's Comeback
Double Blind reports on what's happened inside Lykos Therapeutics since the FDA rejection — the entry of outside investors and the renewed presence of MAPS founder Rick Doblin.
[Source: Double Blind](https://doubleblindmag.com/inside-the-billionaire-takeover-of-lykos-and-rick-doblins-comeback-free/)